Rare disease drugmaker Horizon Therapeutics and Amgen announced a mega deal last year worth $27.8 billion, but the Federal Trade Commission (FTC) is asking for more information before giving them the green light.
Earlier this week, the two revealed that they had received a request for additional information and documentary materials concerning the proposed acquisition. In the SEC filing, the companies also said that they would promptly respond to the FTC’s request.
The acquisition, which would give Amgen access to Horizon’s lead thyroid eye disease drug, Tepezza, was the largest M&A deal of 2022 and represented a premium of approximately 47.9% to the closing price of $78.76 per share on November 29, 2022.
Aside from Tepezza — the first drug approved in the U.S. for the treatment of thyroid eye disease — Amgen is getting its hands on Horizon’s Krystexxa and Uplizna, for the treatment of Gout and neuromyelitis optic spectrum disorder.
